Since the introduction of exogenous factor VIII therapy, several studies have explored the clinical benefits of prophylactic use of factor VIII.
Little research, though, has focused on the economic aspects of this regimen.
We conducted a cost analysis using data from the Orthopedic Outcomes Study, a prospective, cross-national study of the clinical outcomes associated with different patterns of factor VIII utilization to examine the health care costs incurred and expenditures averted in patients receiving on-demand versus prophylactic use of factor VIII in hemophilia.
831 patients with severe hemophilia aged 1 to 31 years, from 19 centers around the world were included in the cost analysis.
Patients were categorized into three groups according to the number of weeks during the study years in which they received prophylactic regimens of factor VIII.
For each subject, we estimated the costs of hospitalization, surgery, days lost from school or work, and factor VIII utilization.
Costs were then stratified by age and by joint score to assess confounding, and a multivariate model developed to determine the relationship between use of factor VIII prophylaxis and total costs, while controlling for potential confounders. (...)
Mots-clés Pascal : Hémophilie, Facteur antihémophilique A, Facteur coagulation, Transfusion, Constituant sang, Prévention, Hémorragie, Analyse coût, Economie santé, Etats Unis, Amérique du Nord, Amérique, Europe, Japon, Asie, Homme, Hémopathie, Coagulopathie, Maladie héréditaire
Mots-clés Pascal anglais : Hemophilia, Factor VIII, Coagulation factor, Transfusion, Blood product, Prevention, Hemorrhage, Cost analysis, Health economy, United States, North America, America, Europe, Japan, Asia, Human, Hemopathy, Coagulopathy, Genetic disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0271534
Code Inist : 002B27D01. Création : 27/11/1998.